About Merus
Merus is a company based in Utrecht (Netherlands) founded in 2003 was acquired by Genmab in December 2025. It operates as a HealthTech. Merus has raised $156.19 million across 11 funding rounds from investors including Pfizer, Genmab and RA Capital. The company has 260 employees as of December 31, 2024. Merus offers products and services including Multiclonics Platform and Clinical Trials. Merus operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Utrecht, Netherlands
- Employees 260 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Merus N.V.
-
Annual Revenue
$36.13 M (USD)-17.78as on Dec 31, 2024
-
Net Profit
-$215.33 M (USD)-38.97as on Dec 31, 2024
-
EBITDA
-$269.6 M (USD)-75.05as on Dec 31, 2024
-
Total Equity Funding
$156.19 M (USD)
in 11 rounds
-
Latest Funding Round
$15 M (USD), Post-IPO
Dec 20, 2018
-
Investors
Pfizer
& 14 more
-
Employee Count
260
as on Dec 31, 2024
-
Acquired by
Genmab
(Dec 12, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Merus
Merus is a publicly listed company on the NASDAQ with ticker symbol MRUS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Merus
Merus offers a comprehensive portfolio of products and services, including Multiclonics Platform and Clinical Trials.
Innovative platform used for developing cancer treatment therapies.
Trials conducted to test new cancer treatment solutions.
People of Merus
Unlock access to complete
Unlock access to complete
Leadership Team
39 people
Software Development Team
17 people
Senior Team
15 people
Finance and Accounting
11 people
Operations Team
10 people
Legal and Compliance
5 people
Product Management Team
4 people
Scientific Team
4 people
Unlock access to complete
Funding Insights of Merus
Merus has successfully raised a total of $156.19M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $15 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Merus
Merus has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Genmab and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Locked | Locked | Locked | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Locked | Locked | Locked | |
|
Investments are made in innovative life science companies globally.
|
Locked | Locked | Locked |
Investor details for Merus
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Merus
Investment portfolio details for Merus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Merus
Detailed financials for Merus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Merus Comparisons
Peer comparison for Merus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Merus
Merus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of Merus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Merus
Complete news archive for Merus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Merus
Merus was founded in 2003 and raised its 1st funding round 3 years after it was founded.
Merus is headquartered in Utrecht, Netherlands.
Merus is a funded company, having raised a total of $156.19M across 11 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Merus is 260.
Annual revenue of Merus is $36.13M as on Dec 31, 2024.
Merus is engaged in the discovery and development of new cancer treatments. The company operates in the biotechnology sector, leveraging its proprietary Multiclonics Platform to create therapeutic solutions. Clinical trials are conducted to test and validate these treatments, aiming to address unmet needs in cancer care. Based in Utrecht, Netherlands, with an additional office in Cambridge, USA, Merus is committed to advancing healthcare through innovative research and development.
Merus's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Merus offers Multiclonics Platform and Clinical Trials.
Yes, Merus is publicly traded on NASDAQ under the ticker symbol MRUS.
Merus has 15 investors. Key investors include Pfizer, Genmab, RA Capital, Life Sciences Partners, and Tekla Capital Management.
The ticker symbol of Merus is MRUS on NASDAQ.